Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TT 11X

Next Previous
Drug Profile

TT 11X

Alternative Names: Allogeneic CD30-Chimeric Antigen Receptor (CAR) Epstein-Bar Virus-Specific T cell therapy (EBVSTs); Allogeneic CD30.CAR-EBVST; CD30.CAR EBV-specific T cells; TT-11X

Latest Information Update: 25 Dec 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tessa Therapeutics
  • Developer Baylor College of Medicine
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Lymphoma

Most Recent Events

  • 20 Dec 2023 Baylor College of Medicine plans a phase I study in Lymphoma in USA in June 2024 (IV, Infusion) (NCT06176690)
  • 28 Oct 2023 No recent reports of development identified for phase-I development in Lymphoma(In adolescents, In children, Second-line therapy or greater, In adults) in USA (IV, Infusion)
  • 22 Jun 2023 Efficacy and adverse events data from phase-I trial in Lymphoma released by Tessa Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top